Precigen Inc.

Precigen Inc.

World Rank (Aug-2026)
6044
Market Cap (Aug-2026)
2.184 Billion USD
Market Cap (Mar-08-2026)
1.175 Billion USD
World Rank (Jan-05-2024)
15,259
Market Cap (Jan-05-2024)
0.326 Billion USD
World Rank (Jul-30-2023)
15,121
Market Cap (Jul-30-2023)
0.341 Billion USD
World Rank (Jan-07-2022)
11,639
Market Cap (Jan-07-2022)
0.668 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
PGEN
Employee Count
191
Employee Count as of Date
As on 2021
Headquarters City/State
Maryland
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
10 Million USD
Annual Operating Income in USD
-111 Million USD
Annual Net Income in USD
-251 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
156 Million USD
Total Liabilities in USD
135 Million USD
Total Equity in USD
21 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Company Website
PRECIGEN, INC.
Company Profile
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The company annual revenue is 103 million USD as on 2020. The headquarters is in USA.
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share